India’s pharmaceutical sector is valued at $50 billion. It has built its reputation on affordability and accessibility. The deaths in Chhindwara tell a different story.
Industry insiders say any rise in duties on Indian generics will squeeze profits for Indian companies, but will also make the drugs costlier for patients in US.
Without widespread access to biosimilars, thousands of cancer patients are losing their battle. Life-saving treatment is not a privilege but a right. The government should understand this.
Leading drugmakers express apprehension over CDSCO’s proposal to permit generic alternatives for key medications, emphasizing the risk of compromised drug quality.
New Delhi: On 18 April, Mumbai-headquartered Marksans Pharma, a drugmaker that supplies generic drugs in over 50 countries around the world, received form 483,...
In clinical trials, tirzepatide by Eli Lilly has shown to reduce body weight by up to 22.5 percent, on average, after about 72 weeks, according to the company.
WHO may be probing allegations of 20 substandard paracetamol & cough syrups by 15 manufacturers from India, but these allegations seem to have little impact on export of medicines.
Provision included in draft bill to be approved by Union cabinet. Existing drugs law mentions product recall, but doesn't specify timelines or system for auditing and accountability.
In a seminal work, former military officers Lt. Gen. D.S. Hooda & Lt. Col. Pavithran Rajan put forth a framework to approach cognitive warfare, called Socio-Technical-Cognitive Battlespace.
India, China and Russia share more contradictions than congruence. Each has a different worldview, as also a different adversary. The rude fact is that BRICS is the most irrelevant of all such groupings.
COMMENTS